There is a symposium at the APA annual meeting this year in May on this I would highly recommend those interested attend.
As luck would have it I am putting together the list for our reading group on this topic at this moment so here you go... These papers cover the problems with long-term use, the supersensitivity psychosis, the fact the prognosis of schizophrenia is much better than has been claimed, that many people do fine going off meds, that prognosis is poorer for those on long term meds, that some patients do better without meds at all, that a subset of patients do not benefit from these drugs because there is nothing dysfunctional about their dopaminergic system, and that patients can do well with extended/intermitted dosing where the neuroleptic burden is less.
From my 100 papers thread:
Andreasen NC, Liu D, Ziebell S, Vora A, Ho BC. Relapse duration, treatment intensity, and brain tissue loss in schizophrenia: a progressive longitudinal MRI study.
Am J Psychiatry 2013; 170:609-615
Chouinard G, Jones BD. Neuroleptic-induced supersensitivity psychosis: clinical and pharmacologic characteristics.
Am J Psychiatry 1980; 137:16-21
Demjaha A, Murray RM, McGuire PK, Kapur S, Howes OD. Dopamine synthesis capacity in patients with treatment-resistant schizophrenia.
Am J Psychiatry 2012; 169:1203-1210
Leff J, Sartorium N, Jablensky A, Korten A, Ernberg G. The International Pilot Study of Schizophrenia: five-year follow-up findings.
Psychol Med 1992; 22:131-145
Wunderink L, Nieboer RM, Wiersma D, Sytema S, Nienhuis FJ. Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical trial.
JAMA Psychiatry 2013; 70:913-920
Additional readings:
Warner R.
Recovery from schizophrenia: psychiatry and political economy. 3rd ed. New York: Brunner-Routledge, 2004
*highly recommended*
Moncrieff J.
The Bitterest Pills: the troubling story of antipsychotic drugs. London: Palgrave Macmillan, 2013
Harrow M, Jobe TH, Faull RN. Do all schizophrenia patients need antipsychotic treatment continuously throughout their lifetime? A 20-year longitudinal study.
Psychol Med 2002; 17:1-11
summary of long-term studies of course of schizophrenia:
http://www.isps-us.org/koehler/longterm_followup.htm
Harrow M, Jobe TH, Faull RN. Does treatment of schizophrenia with antipsychotic medications eliminate or reduce psychosis? A 20-year multi-follow-up study.
Psychol Med 2014; 44:3007-3016
Ciompi L, Harding CM, Lehtinen K. Deep concern.
Schizophr Bull 2010; 36:437-439
Stephens JH. Long-term prognosis and followup in schizophrenia.
Schizophr Bull 1978; 4:25-47
Bola JR, Mosher LR. Treatment of acute psychosis without neuroleptics: two-year outcomes from the Soteria project.
J Nerv Ment Dis 2003; 191:219-29
Bola JR, Mosher LR. At issue: predicting drug-free treatment response in acute psychosis from the Soteria project.
Schizophr Bull 2002; 28:559-575
Remington G, Seeman P, Feingold A, Mann S, Shammi C, Kapur S. “Extended” antipsychotic dosing in the maintenance treatment of schizophrenia: a double-blind, placebo-controlled trial
J Clin Psychiatry 2011; 72:1042-1048
Boshes RA, Manschreck TC. Review of antipsychotic medication administration: a proposal of intermittent dosing.
Schizophr Bull 2002; 28: 203-222